No. of patients | 27 |
Median age [range], years | 61.4 [47.6 - 74.1] |
Gender | Â |
Male | 15 (55.6%) |
Female | 12 (44.4%) |
ECOG performance status score | Â |
0 | 5 (18.5%) |
1 | 7 (25.9%) |
2 | 9 (33.3%) |
3 | 3 (11.1%) |
Unknown | 3 (11.1%) |
First line chemotherapy | Â |
FOLFIRI.3 alternating with Gemcitabine | 7 (25.9%) |
Gemcitabine | 20 (74.1%) |
Pancreatic tumor location | Â |
Head | 14 (51.8%) |
Body | 6 (22.2%) |
Tail | 6 (22.2%) |
Multicentric | 1 (3.7%) |
Metastatic sites | Â |
Liver | 20 (74.1%) |
Peritoneum | 8 (29.6%) |
Lung | 6 (22.2%) |
Distant lymph nodes | 2 (7.4%) |
No. of metastatic sites involved | Â |
1 | 19 (70.4%) |
2 | 7 (25.9%) |
≥ 3 | 1 (3.7%) |
Baseline CA 19–9 level |  |
≤ 37 UI/ml* | 2 (7.4%) |
> 37 UI/ml | 19 (70.4%) |
Unknown | 6 (22.2%) |
No. of cycle | Â |
Mean | 6 |
Median [range] | 4 [1–28] |